Evidence map›Paper›PMID 37605418›Full record

ArticleCombinatorial chemistry & high throughput screening2024

Conjugation of Doxorubicin and Carbon-based-nanostructures for Drug Delivery against HT-29 Colon Cancer Cells.

Kaveh Jafari Aghdam, Bahare Sabeti, Fereshteh Chekin, Maral Mashreghi

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kaveh Jafari AghdamDepartment of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
Bahare SabetiDepartment of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
Fereshteh ChekinDepartment of Chemistry, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
Maral MashreghiDepartment of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
Islamic Azad University of Ayatollah Amoli · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA drug delivery system is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. Such systems release the drugs at specific amounts in a specific site. The carbon based-nanomaterials have been actively used as drug carriers to treat various cancer.

objectiveThis study aimed to evaluate the cytotoxic effects of DOX-GO, DOX-OMC and DOXCNT in colon cancer cells (HT29).

methodsWe reported platforms based on graphene oxide (GO), ordered mesoporous carbon (OMC) and carbon nanotubes (CNT) to conjugate with doxorubicin (DOX). The conjugation of DOX with carbon nanomaterial was investigated by UV-Vis spectroscopy, field emission scanning electron microscope (FE-SEM) and cyclic voltammetry (CV) methods.

resultsWe showed that graphene oxide was a highly efficient matrix. Efficient loading of DOX, 89%, 78%, and 73.5% at pH 7.0 was seen onto GO, OMC and CNT, respectively. Upon pH 4. 0 after 15 h, 69%, 61% and 61% of DOX could be released from the DOX-GO, DOX-OMC and DOX-CNT, respectively, which illustrated the significant benefits of the developed approach for carbon nanomaterial applications.

conclusionThe nanohybrids based on DOX-carbon nanomaterial, because of their unique physical and chemical properties, will remarkably enhance the anti-cancer activity.

Indexed as

Colonic NeoplasmsDoxorubicinDrug Delivery SystemsGraphiteNanotubes, CarbonAntibiotics, AntineoplasticAntineoplastic AgentsCarbonCell ProliferationCell SurvivalDrug CarriersDrug Screening Assays, AntitumorHT29 CellsHumansNanostructuresAntibiotics, AntineoplasticAntineoplastic AgentsCarbonDoxorubicinDrug Carriersgraphene oxideGraphiteNanotubes, Carboncarbon nanotubescolon cancer cells.cyclic voltammetry (CV)Doxorubicingraphene oxideordered mesoporous carbon

Identifiers

PMID37605418
OpenAlexW4386046207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.